Please assess the completion status of the following clinical trial:

Trial Title: Analgesic Efficacy and Safety Study of Naproxcinod in Subjects With Osteoarthritis of the Knee

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women (40 or older) with a diagnosis of primary OA of the knee~* Must be a current chronic user of NSAIDS or acetaminophen~* Must discontinue all analgesic therapy at screening~Exclusion Criteria:~* Uncontrolled hypertension or diabetes~* Hepatic or renal impairment~* Current or expected use of anticoagulant~* A history of alcohol or drug abuse~* Candidates for imminent joint replacement~* Diagnosis of gastric or duodenal ulceration and/or history of significant gastro-duodenal bleeding, within the last 6 months~* Current medical disease that could confound or interfere with the evaluation of efficacy~* Participation within 30 days prior to screening in another investigational study

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo bid (Type: PLACEBO_COMPARATOR): At 13 weeks, the patients receiving placebo were re-randomized to receive either naproxcinod 375 mg bid or naproxcinod 750 mg bid in a 1:1 ratio in the 301E study.
- Naproxcinod 375 mg bid (Type: EXPERIMENTAL): None
- Naproxen 500 mg bid (Type: ACTIVE_COMPARATOR): None
- Naproxcinod 750 mg bid (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).